Showing results (31-40 of 110) with videos related to
Sort By:
Pageof 11
European Journal of Haematology|April 24, 2023
Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantationBernd Metzner, Thomas H Müller, Jochen Casper, et al.Blood|December 3, 2017
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL NetworkSietse M Aukema, Eva Hoster, Andreas Rosenwald, et al.Clinical Endocrinology|November 7, 2021
Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case seriesViktoria F Koehler, Carmina T Fuss, Christina M Berr, et al.Vaccine|July 29, 2006
Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titersMaria Kaml, Ilka Weiskirchner, Michael Keller, et al.Journal of Hematology & Oncology|September 13, 2014
Long-term follow-up of cytogenetically normal CEBPA-mutated AMLFriederike Pastore, Daniela Kling, Eva Hoster, et al.BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissueElena Hartmann, Verònica Fernàndez, Victor Moreno, et al.Leukemia|July 26, 2023
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, et al.Annals of Hematology|March 8, 2024
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study GroupGabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, et al.Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.Pageof 11